These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14715467)

  • 21. The Potential Role of Toll-Like Receptor 4 in Mediating Dopaminergic Cell Loss and Alpha-Synuclein Expression in the Acute MPTP Mouse Model of Parkinson's Disease.
    Mariucci G; Pagiotti R; Galli F; Romani L; Conte C
    J Mol Neurosci; 2018 Apr; 64(4):611-618. PubMed ID: 29589201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Marsden CD; Jenner PG
    Ciba Found Symp; 1987; 126():239-56. PubMed ID: 3556086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
    Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
    J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
    Chattopadhyay M; Chowdhury AR; Feng T; Assenmacher CA; Radaelli E; Guengerich FP; Avadhani NG
    J Biol Chem; 2019 Jun; 294(26):10336-10348. PubMed ID: 31113867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
    Visanji NP; Orsi A; Johnston TH; Howson PA; Dixon K; Callizot N; Brotchie JM; Rees DD
    FASEB J; 2008 Jul; 22(7):2488-97. PubMed ID: 18364399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoquinoline neurotoxins in the brain and Parkinson's disease.
    Nagatsu T
    Neurosci Res; 1997 Oct; 29(2):99-111. PubMed ID: 9359458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.
    Gerlach M; Riederer P; Przuntek H; Youdim MB
    Eur J Pharmacol; 1991 Dec; 208(4):273-86. PubMed ID: 1815982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.
    Battino M; Littarru GP; Gorini A; Villa RF
    Neurochem Res; 1996 Dec; 21(12):1505-14. PubMed ID: 8953566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease.
    Kinemuchi H; Fowler CJ; Tipton KF
    Neurochem Int; 1987; 11(4):359-73. PubMed ID: 20501182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP
    Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J
    J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired CBS-H
    Yuan YQ; Wang YL; Yuan BS; Yuan X; Hou XO; Bian JS; Liu CF; Hu LF
    Brain Behav Immun; 2018 Jan; 67():77-90. PubMed ID: 28774789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP.
    Lam CS; Korzh V; Strahle U
    Eur J Neurosci; 2005 Mar; 21(6):1758-62. PubMed ID: 15845104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Vaglini F; Pardini C; Viaggi C; Bartoli C; Dinucci D; Corsini GU
    J Neurochem; 2004 Oct; 91(2):285-98. PubMed ID: 15447662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B.
    Rodríguez S; Ito T; He XJ; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):127-33. PubMed ID: 21795029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
    Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
    Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.
    Qiao C; Zhang Q; Jiang Q; Zhang T; Chen M; Fan Y; Ding J; Lu M; Hu G
    J Neuroinflammation; 2018 Jul; 15(1):193. PubMed ID: 29966531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
    Choi DY; Lee MK; Hong JT
    Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.